CSIMarket Company Name, Ticker, Customers, else..


Avalo Therapeutics Inc   (NASDAQ: AVTX)
Other Ticker:  
 

Avalo Therapeutics Inc

AVTX's Fundamental analysis



Looking into Avalo Therapeutics Inc growth rates, revenue grew by 5.51 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 3051

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Avalo Therapeutics Inc realized net income compared to net loss a year ago in III. Quarter 2024

• More on AVTX's Growth


Avalo Therapeutics Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 2.21 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 193.74.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.


• More on AVTX's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 30,333
 Net Income/Employee (TTM) $ -294,741
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 0.45

Avalo Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 2.21 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 193.74.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.

Avalo Therapeutics Inc Price to Book Ratio is at 7.53 lower than Industry Avg. of 1351.91. and higher than S&P 500 Avg. of 0.01

• More on AVTX's Valuation

•  Market Capitalization (Millions $) 159
•  Shares Outstanding (Millions) 24
•  Employees 27
•  Revenues (TTM) (Millions $) 1
•  Net Income (TTM) (Millions $) -8
•  Cash Flow (TTM) (Millions $) 72
•  Capital Exp. (TTM) (Millions $) -
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 30,333
•  Net Income/Employee(TTM) $ -294,741
•  Receivable Turnover Ratio (TTM) -
•  Tangible Book Value (Per Share $) 0.45

•  Market Capitalization (Millions $) 159
•  Shares Outstanding (Millions) 24
•  Employees 27
•  Revenues (TTM) (Millions $) 1
•  Net Income (TTM) (Millions $) -8
•  Cash Flow (TTM) (Millions $) 72
•  Capital Exp. (TTM) (Millions $) -





  Ratio
•   Capital Ratio (MRQ) 1.42
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 7.32
•  Asset Turnover Ratio (TTM) 0.01
•  Inventory Turnover Ratio (TTM) -





Avalo Therapeutics Inc net profit margin of 9251.81 % is currently ranking no. 3 in Major Pharmaceutical Preparations industry, ranking no. 3 in Healthcare sector and number 9 in S&P 500.

• More on AVTX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com